Abstract
Cervical cancer is caused by persistent human papillomavirus (HPV) infection. However, HPV prevalence data and survival rates among HPV-infected women are scare in Saudi Arabia. This study assessed the prevalence of HPV genotypes in a 10 year time-frame. Cervical biopsy specimens underwent HPV detection, HPV viral load using qPCR, HPV genotyping, p16INK4a expression measurement using immunohistochemistry. Kaplan-Meier plots were constructed to analyze overall survival rates. Of the 316 cervical specimens examined, HPV was detected in 96 (30.4%); 37.3% had cervical cancer; 14.2% cervical intraepithelial neoplasia (CIN) III, 4.1% CIN II, and 17.0% CIN I. A significant association was found between HPV-16 viral load and disease progression (P < .001, Mann-Whitney U) and between HPV presence and cervical cancer (χ2, 56.78; P < .001). The expression of p16INK4a was a significant predictor of survival: women who had p16INK4a overexpression had poorer survival rates (multivariate Cox regression, hazard ratio, 3.2; 95% CI, 1.1-8.8). In addition, multivariate models with HPV status and cervical cancer diagnosis showed that HPV status was a significant predictor of survival: HPV-positive women had better survival rates than HPV-negative women (haza. These findings suggest that implementing cervical cancer and HPV screening programs may decrease cervical cancer rates and improve survival rates of women in Saudi Arabia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Infectious Diseases Program, National Center for Biotechnology in King Abdulaziz City for Science and Technology and the Research Centre administration at King Faisal Specialist Hospital and Research Centre.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted according to the World Medical Association Declaration of Helsinki. The study protocol was approved by the Research Advisory Council (Ethics Committee) at KFSHRC (No. 2150001). The need for obtaining written informed patient consent was waived by the ethics committee for the present study because the cervical biopsies were archived, and the collected patient data were coded and thus deidentified.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Declarations of interest: none
Data Availability
Data is available upon request